Ullem Scott B.

EW CFO Ullem Scott B. sold 13,000 shares (13.0K shares) for $1,040,544.36 ($1.0M) on 2026-04-09 at $80.04 blended average

Ullem Scott B., Chief Financial Officer of Edwards Lifesciences, executed 2 separate sales totaling 13,000 shares for $1,040,544.36 in a single trading day at prices of $80.50 and $79.79, representing a -24.7% reduction in his shareholdings from 52,699 to 39,699 shares. The sales occurred at $80.04 (blended average), modestly above the current price of $79.15 but well above the 52-week low of $67.07, during a period when the stock is -9.2% from its 52-week high and -7.7% over the prior 30 days. At EW, his prior 3 measurable sales all achieved negative 90-day returns (well-timed outcomes per his same-ticker history), though the cross-ticker track record shows only 50.00% well-timed rate across 20 prior sells. The company's fundamentals remain solid with $1.6B quarterly revenue, $291.1M net income, and +11.6% annual revenue growth, though the P/E of 43.02 reflects an elevated valuation. This substantial reduction in insider holdings warrants monitoring in context of the stock's recent price weakness.

CFO Ullem Scott B. sold 13,000 shares for $1.1M; 3 of 5 prior EW sales were well-timed at 90-day mark

CFO Ullem Scott B. executed 2 separate sales totaling 13,000 shares for $1,103,895.79 on 2026-03-11, reducing holdings by 24.7% from 52,699 to 39,699 shares. The blended average price of $84.92 is 0.2% below the current price of $85.09, and notably near the 52-week high of $87.18. Examining his prior trade timing at Edwards Lifesciences, 3 of 5 earlier sales showed negative 90-day returns (well-timed sells), suggesting pattern sensitivity to subsequent price declines. However, his cross-ticker track record shows an average 90-day return of -2.9% across 20 prior sells, with a 55.00% well-timed rate—modestly above random. The sale occurs within a context of strong fundamentals: $1.6B quarterly revenue, +11.6% annual growth, and $291.1M net income, though the P/E of 46.24 reflects a valuation premium.

CFO Ullem Scott B. sold 7,700 shares of EW at $84.47 on 2025-12-09 for $650,412.07; stock down -9.4% annually.

Ullem Scott B., Chief Financial Officer, sold 7,700 shares (7.7K shares) at $84.47 on 2025-12-09, reducing his holdings from 47,598 shares to 39,898 shares (a -16.2% reduction). His cross-ticker track record shows 20 prior sells with an average 90-day return of -4.0% and a well-timed rate of 50.00%, indicating mixed execution timing. At EW specifically, his prior 3 measurable same-ticker sells were all positively resolved (90-day returns of +4.7%, +7.0%, and +10.2%), meaning the stock rose after each sale — the opposite of what would constitute well-timed selling. Current stock price of $83.28 is -4.1% from the 52-week high of $86.82, and fundamentals show annual revenue growth of -9.4% against a P/E of 35.29 and market cap of $48,327,384,000.00. The transaction itself appears routine and discretionary (no 10b5-1 flag noted), but the juxtaposition of prior poorly-timed same-ticker sales against persistent revenue headwinds warrants tracking.

CFO Ullem Scott B. sold 13,000 shares at avg $83.08; holds 39,898 shares post-sale (-24.6% reduction)

Ullem Scott B., Chief Financial Officer of Edwards Lifesciences, executed 2 separate sales totaling 13,000 shares for $1,080,093.42 on 2025-11-10, reducing his holdings by 24.6% from 52,898 to 39,898 shares. The blended average price of $83.08 compares closely to the current price of $84.08, placing the transaction near recent trading levels. His cross-ticker track record shows 20 prior sells with an average 90-day return of -4.8% and a 55.00% well-timed rate, while his 5 prior EW-specific sales were not well-timed at the 90-day mark (0 of 5 fell during stock declines). The company's fundamentals include a -9.4% annual revenue decline, a P/E of 35.63, and recent quarterly net income of $291.1M against revenue of $1.6B, indicating a relatively elevated valuation amid contracting revenue.

CFO Ullem Scott B. sold 11,250 shares of EW at $74.40 for $837.0K, reducing holdings 21.5% to 41.1K shares.

Ullem Scott B., CVP and Chief Financial Officer of Edwards Lifesciences, executed a substantial sale of 11,250 shares at $74.40 on 2025-05-09, reducing his holdings by 21.5% from 52.3K to 41.1K shares. Across his cross-ticker open-market history, the insider's 19 prior sells have shown a 73.33% well-timed rate at the 90-day mark, though his average 90-day return after sells is -8.5%, indicating the stock typically declined after he sold. At Edwards Lifesciences specifically, his 5 prior trades show mixed timing: 1 of 1 measurable 90-day outcomes was well-timed (the 2024-12-09 sale with -1.9% return), though more recent same-ticker sales (in Feb-Mar 2025) lack 90-day outcome data yet. The stock currently trades at $73.68, down 21.4% from its 52-week high of $93.78 and up 5.4% over the past 30 days, placing this sale in a context of elevated price volatility and the company reporting a -9.4% annual revenue decline despite maintaining a low P/E of 10.33.

CFO Scott Ullem sells 11,250 shares of EW at $70.87; reduces stake 27% to 30.4K shares amid -25.6% pullback from 52-week high.

CFO Scott Ullem sold 11,250 shares at $70.87 on 2025-03-26, reducing his holdings by 27.0% to 30.4K shares. This sale occurs while Edwards Lifesciences stock trades 25.6% below its 52-week high of $95.56 and reflects a -2.3% drop over the past 30 days and -6.4% over 90 days. At the same-ticker level, Ullem has executed 5 prior trades at EW, including two recent sells on 2025-02-28 and another on 2025-02-13, showing active portfolio activity. His cross-ticker track record across 18 prior sells shows a 73.33% well-timed rate at the 90-day mark, though prior same-ticker measurable outcomes are mixed: one 30-day outcome of -8.5% and one 90-day outcome of -24.5% (2024-05-21). The company's fundamentals show a compressed P/E of 6.03 and annual revenue decline of -9.4%, creating a backdrop of operational headwinds alongside the recent stock underperformance.

CFO Scott B. Ullem sells 11,250 shares of Edwards Lifesciences for $796.3K at $70.78 avg price

CVP and Chief Financial Officer Ullem Scott B. executed 2 separate sales totaling 11,250 shares for $796,326.99 on 2025-02-28, reducing his holdings by -27.0% from 41,637 to 30,387 shares. The sales occurred at prices of $71.38 and $70.52, near the stock's current price of $71.62, versus the 52-week high of $95.56. His prior 5 trades at Edwards Lifesciences show a 3 of 3 well-timed pattern at the 90-day mark, with all three measurable outcomes showing negative 90-day returns (-24.5%, -25.7%, -26.2%), indicating a consistent pattern of selling ahead of price declines at this ticker. The company's revenue declined -9.4% year-over-year and trades at a P/E of 6.07, near historical lows, while the insider's cross-ticker track record shows a 71.43% well-timed sell rate with average 90-day returns of -9.0%.

CFO Ullem Scott B. sold 11,250 shares of EW at $75.76 (Feb 13), reducing stake 26.9%; stock +7.0% in 30 days, -20.5% from 52-week high.

Ullem Scott B., CVP and Chief Financial Officer, sold 11,250 shares of Edwards Lifesciences at $75.76 on 2025-02-13, reducing his holdings from 41,811 to 30,561 shares (a 26.9% reduction). At the time of sale, the stock was trading below its 52-week high of $95.56, though it has since recovered +7.0% over 30 days and stands at $76.00 currently. His prior four measurable sales at EW all posted negative 90-day returns, with a 100% well-timed rate (4 of 4), suggesting a track record of selling before declines at this specific ticker. Cross-ticker, his 15 prior sales averaged a 90d return of -9.0% with a 71.43% well-timed rate. The company fundamentals remain solid: $1.4B quarterly revenue with +11.6% annual growth, $3.1B net income, and a P/E of 10.78. The sale size represents a material reduction in CFO holdings but does not signal company-level distress, only a discrete reduction by one executive.

CFO Ullem Scott B. sold 11,250 shares of Edwards Lifesciences (EW) for $806.4K on 2024-12-09; all 5 prior EW sales were well-timed at 90-day mark.

Ullem Scott B., CFO of Edwards Lifesciences, executed an open-market sale of 11,250 shares at $71.68 on 2024-12-09, reducing his holdings by 26.9% from 41,811 to 30,561 shares. His prior trading pattern at this ticker is notably consistent: all 5 prior sales at EW were well-timed at the 90-day mark, with cumulative 90-day returns of -24.5%, -25.7%, -26.2%, -2.6%, and -3.3%, indicating the stock declined after each sale. His cross-ticker track record shows a 71.43% well-timed rate across 14 prior sells with an average 90-day return of -9.0%, suggesting a demonstrated ability to exit before downturns. The current price of $70.90 represents a -25.8% decline from the 52-week high of $95.56, and the stock is off 30 days following a +7.0% rebound, positioning this sale within a volatile backdrop where the insider's historical pattern may carry informational weight.